The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

Morgan Stanley easily beat fourth-quarter profit and revenue estimates on strong equity trading and IPO activity.

UnitedHealth beat fourth-quarter earnings forecast, though revenue fell short and medical costs ran high, hitting the Dow ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Eli Lilly stock undercut its 50-day line on Jan. 14 after cutting its fourth-quarter and 2024 outlook. Is LLY stock a sell ...

Michael Osso is chief executive officer of the Crohn's & Colitis Foundation. "Eli Lilly Receives FDA Approval for Crohn's Disease Treatment," at 4:40 p.m. ET, and in a subsequent update, incorrectly ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

As spot Bitcoin exchange-traded funds (ETFs) mark their first anniversary and Ethereum ETFs reach the six-month milestone, ...

US stocks surged on Wednesday, fueled by a slowdown in core inflation and better-than-expected earnings from major banks. The ...

TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...